Home › Companies › Akero Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Akero Therapeutics, Inc.’s Form 8-K, filed 2025-12-03 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Akero Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Akero Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-12-03 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Proposal 1: The Merger Proposal To adopt the Agreement and Plan of Merger (as may be amended, modified or supplemented from time to time, the " Merger Agreement "), dated October 9, 2025, by and among the Company, Parent, and NN Invest Sub, Inc, a Delaware cor | 66,887,600 | 91,361 | 50,147 | -- | 0 | Majority: yes |
| Proposal 2: The Compensation Proposal To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by the Company to its named executive officers in connection with the Merger | 65,621,066 | 1,316,708 | 91,334 | -- | 0 | Majority: yes |
Source: Akero Therapeutics, Inc., Form 8-K, filed with the SEC on 2025-12-03 — read the filing on EDGAR.
Each item below shows how the 276 asset managers that disclosed a Akero Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Akero Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 8 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Akero Therapeutics, Inc.’s own tally for this item (“Proposal 2: The Compensation Proposal To approve, on an advisory, non-binding basis, the payment of certain compensation that may be paid or become payable by the Company to its named executive officers in connection wit”): 65,621,066 for, 1,316,708 against, per its Form 8-K filed 2025-12-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
The 269 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 8,375,099 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 5,873,305 | 0 | 0 | 0 | For |
| GENERAL ATLANTIC, L.P. | 5,733,989 | 0 | 0 | 0 | For |
| BlackRock | 5,267,427 | 340 | 0 | 0 | For |
| Vanguard | 4,183,108 | 5 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,000,000 | 0 | 0 | 0 | For |
| Fidelity | 3,888,571 | 0 | 0 | 0 | For |
| State Street | 3,121,352 | 3,077 | 0 | 0 | For |
| GLAZER CAPITAL, LLC | 3,096,210 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 2,332,745 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,786,517 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,371,320 | 0 | 0 | 0 | For |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | 1,318,902 | 0 | 0 | 0 | For |
| Charles Schwab | 1,210,926 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 1,125,359 | 0 | 0 | 0 | For |
| American Century | 1,114,031 | 1,492 | 0 | 0 | For |
| Logos Global Management LP | 1,000,000 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 884,572 | 0 | 0 | 0 | For |
| Loomis Sayles | 800,413 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 763,523 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 748,741 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 745,615 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 624,526 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 619,821 | 0 | 0 | 0 | For |
| Gabelli | 569,238 | 0 | 0 | 0 | For |
Showing the 25 largest of 269 asset managers. See all 269 in the interactive database.
Combines 8 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Akero Therapeutics, Inc.’s own tally for this item (“Proposal 1: The Merger Proposal To adopt the Agreement and Plan of Merger (as may be amended, modified or supplemented from time to time, the " Merger Agreement "), dated October 9, 2025, by and among the Company, Parent”): 66,887,600 for, 91,361 against, per its Form 8-K filed 2025-12-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
The 76 asset managers below cast 99.5% of the shares they voted on this item FOR (17,308,580 for, 70,867 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,857,586 | 0 | 0 | 0 | For |
| BlackRock | 2,861,394 | 0 | 0 | 0 | For |
| State Street | 1,786,818 | 0 | 0 | 0 | For |
| Fidelity | 1,609,139 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,371,320 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 884,572 | 0 | 0 | 0 | For |
| Charles Schwab | 605,436 | 0 | 0 | 0 | For |
| American Century | 530,169 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 369,896 | 0 | 0 | 0 | For |
| Dimensional | 366,061 | 0 | 0 | 0 | For |
| Loomis Sayles | 290,788 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 256,627 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 214,300 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 213,576 | 0 | 0 | 0 | For |
| Equitable | 163,470 | 0 | 0 | 0 | For |
| TIAA | 154,717 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 145,609 | 0 | 0 | 0 | For |
| Calamos | 125,648 | 0 | 0 | 0 | For |
| GMO | 116,524 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 116,498 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 103,568 | 0 | 0 | 0 | For |
| Hartford | 102,934 | 0 | 0 | 0 | For |
| Lincoln Financial | 97,204 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 87,331 | 0 | 0 | 0 | For |
| Brighthouse | 86,436 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.
89% fund support · no official result
The 75 asset managers below cast 89% of the shares they voted on this item FOR (15,432,744 for, 1,941,206 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,857,586 | 0 | 0 | 0 | For |
| BlackRock | 2,861,394 | 0 | 0 | 0 | For |
| State Street | 6,716 | 1,780,102 | 0 | 0 | Against |
| Fidelity | 1,609,139 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,371,320 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 884,572 | 0 | 0 | 0 | For |
| Charles Schwab | 605,436 | 0 | 0 | 0 | For |
| American Century | 530,169 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 369,896 | 0 | 0 | 0 | For |
| Dimensional | 366,061 | 0 | 0 | 0 | For |
| Loomis Sayles | 290,788 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 256,627 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 214,300 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 213,576 | 0 | 0 | 0 | For |
| Equitable | 163,470 | 0 | 0 | 0 | For |
| TIAA | 154,717 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 145,609 | 0 | 0 | 0 | For |
| Calamos | 125,648 | 0 | 0 | 0 | For |
| GMO | 116,524 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 116,498 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 103,568 | 0 | 0 | 0 | For |
| Hartford | 102,934 | 0 | 0 | 0 | For |
| Lincoln Financial | 46,804 | 50,400 | 0 | 0 | Against |
| AIG/SunAmerica | 87,331 | 0 | 0 | 0 | For |
| Brighthouse | 80,940 | 0 | 5,496 | 0 | For |
Showing the 25 largest of 75 asset managers. See all 75 in the interactive database.
Combines 2 wordings of this item as funds reported it.
1% fund support · no official result
The 6 asset managers below cast 1% of the shares they voted on this item FOR (290 for, 22,336 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 0 | 21,926 | 0 | 0 | Against |
| Impact Investors, Inc | 0 | 410 | 0 | 0 | Against |
| TD Waterhouse Canada Inc. | 200 | 0 | 0 | 0 | For |
| BlackRock | 76 | 0 | 0 | 0 | For |
| Coyle Financial Counsel LLC | 14 | 0 | 0 | 0 | For |
| Taconic Capital Advisors LP | 0 | 0 | 0 | 0 | -- |
Ranked by the number of Akero Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Janus Henderson | 8,375,099 |
| 2 | RTW INVESTMENTS, LP | 5,873,305 |
| 3 | GENERAL ATLANTIC, L.P. | 5,733,989 |
| 4 | BlackRock | 5,267,767 |
| 5 | Vanguard | 4,183,114 |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,000,000 |
| 7 | Fidelity | 3,888,571 |
| 8 | State Street | 3,124,429 |
| 9 | GLAZER CAPITAL, LLC | 3,096,210 |
| 10 | Deep Track Capital, LP | 2,332,745 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to Akero Therapeutics, Inc. for the 2025-2026 season, so there is no denominator to divide by.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Akero Therapeutics, Inc.'s shareholder meeting held 2025-12-02, in the 2025-2026 proxy season, 276 asset managers reported how they voted in their SEC Form N-PX filings, covering 944 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory, non- binding basis, the payment of certain compensation that may be… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Akero Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-12-03.
Akero Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).